Ascletis Pharma, ASC39, obesity treatment, oral obesity drug, amylin receptor agonist, selective amylin agonist, FDA IND application, weight management, metabolic diseases, AISBDD, ASC30

Hong Kong, China, October 26, 2026 Ascletis Pharma Inc. announced that it has submitted an Investigational New Drug (IND)...